Nuwellis Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceGlobeNewsWire • 07/23/25
Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025GlobeNewsWire • 07/22/25
Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure CareGlobeNewsWire • 07/17/25
Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Leader in Fluid Management InnovationGlobeNewsWire • 07/15/25
Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment OptionGlobeNewsWire • 06/10/25
Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 05/13/25
Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational EfficiencyGlobeNewsWire • 05/12/25
Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital SystemsGlobeNewsWire • 05/08/25
Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves PrecisionGlobeNewsWire • 04/24/25
Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025GlobeNewsWire • 04/22/25
Nuwellis, Inc. (NUWE) Reports Q4 Loss, Lags Revenue Estimates (Revised)Zacks Investment Research • 03/11/25
JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study AnalysisGlobeNewsWire • 02/20/25
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025GlobeNewsWire • 02/18/25
Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent HighlightsGlobeNewsWire • 11/11/24